Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: A prospective study

The Lancet Respiratory Medicine

Volumn 1, Issue 3, 2013, Pages 224-232

  Chalmers, James D ^a   McHugh, Brian J ^b   Doherty, Catherine ^c   Smith, Maeve P ^d   Govan, John R ^c   Kilpatrick, David C ^e   Hill, Adam T ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BRONCHIECTASIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MANNOSE BINDING LECTIN DEFICIENCY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; THORAX RADIOGRAPHY; UNITED KINGDOM;

AGED; BACTERIAL LOAD; BRONCHIECTASIS; DISEASE PROGRESSION; EFFECT MODIFIER, EPIDEMIOLOGIC; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; GREAT BRITAIN; HUMANS; IMMUNITY, INNATE; MALE; MANNOSE-BINDING LECTIN; METABOLISM, INBORN ERRORS; MIDDLE AGED; PROSPECTIVE STUDIES; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84877148300     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70001-8     Document Type: Article

References (36)

1. Pasteur MC, Bilton D, Hill AT British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65(suppl 1):i1-58.
2. Cole PJ Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986, 147:6-15.
3. Fuschillo S, De Felice A, Balzano G Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008, 31:396-406.
4. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000, 162:1277-1284.
5. Kilpatrick DC Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta 2002, 1572:401-413.
6. Neth O, Jack DL, Dodds AW Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000, 68:688-693.
7. Moller-Kristensen M, Ip WK, Shi L, et al. Deficiency of mannose-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa. J Immunol 2006, 176:1769-1775.
8. Thiel S, Vorup-Jensen T, Stover CM, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997, 386:506-510.
9. Wallis R Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway. Immunobiology 2007, 212:289-299.
10. Hodge S, Matthews G, Dean MM, et al. Therapeutic role for mannose-binding lectin in cigarette smoke-induced lung inflammation? Evidence from a murine model. Am J Respir Cell Mol Biol 2010, 42:235-242.
11. Wang M, Chen Y, Zhang Y, Zhang L, Lu X, Chen Z Mannan-binding lectin directly interacts with toll-like receptor 4 and suppresses lipopolysaccharide-induced cytokine secretion from THP-1 cells. Cell Mol Immunol 2011, 8:265-275.
12. Eisen DP Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun 2010, 2:114-122.
13. Fevang B, Mollnes TE, Holm AM, et al. Common variable immunodeficiency and the complement system: low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol 2005, 142:576-584.
14. Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008, 118:1040-1049.
15. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999, 104:431-437.
16. Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC Impact of mannose binding lectin (MBL) insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 2011, 21:271-282.
17. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995, 165:261-267.
18. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
19. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R Validation of the St George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997, 156:536-541.
20. Murray MP, Turnbull K, MacQuarrie S, Hill AT Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34:125-131.
21. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ Effects of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011, 342:d2549.
22. Murray MP, Govan JRW, Docherty CJ, et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183:491-499.
23. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012, 186:657-665.
24. Kilpatrick DC, Bevan BH, Liston WA Association between mannan binding protein deficiency and recurrent miscarriage. Mol Hum Reprod 1995, 1:2501-2505.
25. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
26. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009, 34:843-849.
27. Lin CL, Siu LK, Lin JC, et al. Mannose binding lectin gene polymorphism contributes to recurrent of infection exacerbation in patients with COPD. Chest 2011, 139:43-51.
28. Sørensen CM, Hansen TK, Steffensen R, Jensenius JC, Thiel S Hormonal regulation of mannan-binding lectin synthesis in hepatocytes. Clin Exp Immunol 2006, 145:173-182.
29. Kilpatrick DC, Chalmers JD, MacDonald SL, et al. Stable bronchiectasis is associated with low serum L-ficolin concentrations. Clin Respir J 2009, 3:29-33.
30. MacFarlane JG, Jary H, Hester KLM, et al. Low serum mannose-binding lectin level is not associated with disease severity in non-cystic fibrosis bronchiectasis. Innate Immun 2012, 18:787-792.
31. Martinez-Garcia MA, Soler-Cataluna JJ, Donat-Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011, 140:1130-1137.
32. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178:139-148.
33. Boyton RJ, Smith J, Ward R, et al. HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis. Am J Respir Crit Care Med 2006, 173:327-333.
34. Boyton RJ, Smith J, Jones M, et al. Human leucocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity. Clin Exp Immunol 2008, 152:95-101.
35. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005, 94(suppl):S1-63.
36. Garred P, Pressler T, Lanng S, et al. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Paediatr Pulmonol 2002, 33:201-207.